ChinaNationalAccordMedicinesCorporationLtd.
FirstQuarterlyReport2020
April2020
SectionI.ImportantNotes
BoardofDirectorsandtheSupervisoryCommitteeofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)anditsdirectors,supervisorsandseniorexecutivesshouldguaranteethereality,accuracyandcompletionofthequarterlyreport,therearenoanyfictitiousstatements,misleadingstatementsorimportantomissionscarriedinthisreport,andshalltakelegalresponsibilities,individualand/orjoint.AllDirectorsareattendedtheBoardMeetingforQuarterlyReportdeliberation.LinZhaoxiongpersoninchargeoftheCompany,WeiPingxiao,personinchargerofaccountingworksandWangYing,personinchargerofaccountingorgan(accountingofficer)herebyconfirmthattheFinancialReportofthisQuarterlyReportisauthentic,accurateandcomplete.
SectionII.CompanyprofileI.Mainaccountingdataandfinancialindexes
Whetherithasretroactiveadjustmentorre-statementonpreviousaccountingdata
√Yes□NoRetrospectiveadjustmentorrestatementreasonsBusinesscombinationunderthesamecontrol
CurrentPeriod | Sameperiodoflastyear | Changesofthisperiodoversameperiodoflastyear | ||
Beforeadjustment | Afteradjustment | Afteradjustment | ||
Operatingincome(RMB) | 12,824,196,278.66 | 11,879,309,078.82 | 12,071,656,553.13 | 6.23% |
Netprofitattributabletoshareholdersofthelistedcompany(RMB)(note1) | 248,800,655.88 | 300,149,012.08 | 299,451,036.34 | -16.91% |
Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB) | 241,724,850.95 | 297,420,355.99 | 297,420,355.99 | -18.73% |
Netcashflowarisingfromoperatingactivities(RMB) | -688,273,848.63 | -759,367,352.29 | -788,378,287.50 | 12.70% |
Basicearningspershare(RMB/Share)(note1) | 0.58 | 0.70 | 0.70 | -17.14% |
Dilutedearningspershare(RMB/Share) | 0.58 | 0.70 | 0.70 | -17.14% |
WeightedaverageROE(note1) | 1.92% | 2.55% | 2.52% | 0.60percentagepointdown |
Attheendofthereportingperiod | Attheendoflastyear | Changesofthisperiod-endoversameperiod-endoflastyear | ||
Beforeadjustment | Afteradjustment | Afteradjustment | ||
Totalassets(RMB) | 36,882,640,680.62 | 30,855,284,546.74 | 34,030,520,217.82 | 8.38% |
Netassetsattributabletoshareholderoflistedcompany(RMB) | 13,062,640,261.41 | 11,918,581,615.36 | 12,911,706,424.61 | 1.17% |
Descriptiononretrospectiveadjustment:
Inthisyear,theCompanyacquired75%equityofPudongNewAreaofShanghaiPharmaceuticalMedicineLtd.underthesamecontrol.WhenpreparingthecomparativestatementoftheconsolidatedstatementforQ1of2020,thepartiesinvolvedinthemergershallberegardedasexistinginthecurrentstatewhenthefinalcontrollingpartystartstoimplementthecontrol,andthepreliminarycomparativestatementshallbeadjusted.Note1:Netprofitattributabletoshareholdersofthelistedcompanyhas16.91%downcomparedwithsameperiodlastyear,mainly
becauseaffectedbytheCOVID-19epidemic,salesgrowthoftheCompanysloweddowninthefirstquarter,atthesametime,changesinindustrypoliciesalsoledtoanarrowingofprofitmargins;whilethebasicEPSdecreasedby17.14%correspondingly.WeightedaverageROEhas0.60percentagepointsdowncomparedwithsameperiodlastyear.Itemsofnon-recurringgainsandlosses
√Applicable□Notapplicable
InRMB
Item | Amountfromyear-begintoperiod-end | Note |
Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | -438,158.53 | Mainlyforstorerent-outandfixedassetdisposallosses. |
Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness) | 13,645,696.75 | MainlyduetotheTaxreliefandvariousspecialgrantsreceivedinthecurrentperiod. |
Switchbackofprovisionfordepreciationofaccountreceivableandcontractassetsthatareindividuallytestedforimpairment | 72,938.17 | |
Consigningfeereceivedforconsignedoperation | 961,488.75 | |
Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | -491,478.52 | |
Othergains/lossessatisfyadefinitionofextraordinarygains/losses | 257,186.89 | |
Less:Impactonincometax | 3,271,286.58 | |
Impactonminorityshareholders’equity(post-tax) | 3,660,582.00 | |
Total | 7,075,804.93 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss
II.Totalnumberofshareholdersattheendofthisreportperiodandtoptenshareholders
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders
Inshares
Totalcommonshareholdersattheendofreportperiod | 26,399 | Totalpreferenceshareholderswithvotingrightsrecoveredat | 0 |
endofreportingperiod(ifapplicable) | ||||||||
Toptenshareholders | ||||||||
Shareholder’sname | Natureofshareholder | Proportionofsharesheld | Amountofsharesheld | Amountofrestrictedsharesheld | Numberofsharepledged/frozen | |||
Stateofshare | Amount | |||||||
SinopharmGroupCo.,Ltd. | State-ownedlegalperson | 56.06% | 239,999,991 | 5,505,770 | ||||
HongKongSecuritiesClearingCompanyLtd | ForeignCorporation | 4.55% | 19,472,330 | |||||
HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | ForeignCorporation | 2.68% | 11,469,644 | |||||
NationalSocialSecurityFund-portfolio118 | Domesticnonstate-ownedCorporation | 1.82% | 7,774,799 | |||||
ChinaNationalPharmaceuticalForeignTradeCorp. | State-ownedCorporation | 1.24% | 5,323,043 | |||||
FidelityInvestmentManagement(HongKong)Limited-Client’sfund | ForeignCorporation | 1.09% | 4,668,607 | |||||
CentralHuijinInvestmentLtd. | State-ownedCorporation | 0.89% | 3,804,400 | |||||
BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | ForeignCorporation | 0.78% | 3,358,761 | |||||
BankofChinaCo.,Ltd.-HarvestHealthcareEquitySecuritiesInvestmentFund | Domesticnonstate-ownedCorporation | 0.67% | 2,862,997 |
Basicendowmentinsurancefund-portfolio15061 | Domesticnonstate-ownedCorporation | 0.55% | 2,364,393 | |||
Toptenshareholderswithunrestrictedsharesheld | ||||||
Shareholder’sname | Amountofunrestrictedsharesheld | Typeofshares | ||||
Type | Amount | |||||
SinopharmGroupCo.,Ltd. | 234,494,221 | RMBordinaryshares | 234,494,221 | |||
HongKongSecuritiesClearingCompanyLtd | 19,472,330 | RMBordinaryshares | 19,472,330 | |||
HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | 11,469,644 | Domesticlistedforeignshares | 11,469,644 | |||
NationalSocialSecurityFund-portfolio118 | 7,774,799 | RMBordinaryshares | 7,774,799 | |||
ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 | |||
FidelityInvestmentManagement(HongKong)Limited-Client’sfund | 4,668,607 | RMBordinaryshares | 4,668,607 | |||
CentralHuijinInvestmentLtd. | 3,804,400 | RMBordinaryshares | 3,804,400 | |||
BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,358,761 | Domesticlistedforeignshares | 3,358,761 | |||
BankofChinaCo.,Ltd.-HarvestHealthcareEquitySecuritiesInvestmentFund | 2,862,997 | RMBordinaryshares | 2,862,997 | |||
Basicendowmentinsurancefund-portfolio15061 | 2,364,393 | RMBordinaryshares | 2,364,393 | |||
Explanationonassociatedrelationshipamongtheaforesaidshareholders | ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentpersonactinginconcertamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. |
Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreementdealinginreportingperiod
□Yes√NoThetoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.TotalshareholderswithpreferredstockheldatPeriod-endandsharesheldbytoptenshareholderswithpreferredstockheld
□Applicable√Notapplicable
SectionIII.SignificantEventsI.Particularsaboutmaterialchangesinitemsofmainaccountingstatementandfinancialindexandexplanationsofreasons
√Applicable□Notapplicable
1.Notesreceivable:adecreaseof264.6581millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-33.59%,mainlybecauseaffectedbytheGPOpolicy,thehospitalcustomerprocurementmodelhaschanged,andthesettlementmethodhasalsochanged;
2.Advancestosuppliers:anincreaseof387.3169millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
99.36%,mainlybecausetheprepaymentofemergencyspecialreservematerialsforthepreventionandcontrolofCOVID-19andtheincreaseintheprepaymentsdueontheimportletterofcredit;
3.Dividendreceivable:adecreaseof834,914.61Yuancomparedwiththebeginningoftheperiod,withagrowthrateof-100.00%,mainlybecausedividendsreceivablefromShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.inthesameperiodoflastyear,thiscompanyhasbeenincludedinthescopeofconsolidationintheperiod,andthereisnobalanceattheconsolidationlevelafterinternaloffset;
4、Intangibleassets:anincreaseof260.2451millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof69.37%,mainlybecausethesalesnetworknewlyrecognizedintheperiodfortheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstore;
5.Goodwill:anincreaseof503.1178millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof49.81%,mainlyresultedbytheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstoreintheperiod;
6.Othernon-currentassets:anincreaseof336.7663millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
435.35%,mainlybecauseinordertopreventingandcontrollingtheCOVID-19,topurchaseemergencyspecialreservematerialsattherequestofthegovernment;
7.Short-termborrowings:anincreaseof1,332.2357millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
91.69%,mainlybecausethesupplychainfinancingandspecialloansforpreventionandcontroloftheCOVID-19epidemicareincreasedinthePeriod;
8.Otherpayables:anincreaseof874.467millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof47.99%,mainlyduetotheequityconsiderationpayableforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbysubsidiaryGuodaDrugstoreintheperiodandthenon-financialinstitutionfundsborrowing;
9.Dividendpayable:anincreaseof37.9886millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof594.56%,mainlyduetothedividendpayabletooriginalshareholdersofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.-thesubsidiaryoftheCompanythatincludedintheconsolidatescopeinthePeriod;10、Deferredtaxliabilities:anincreaseof61.9156millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
52.16%,mainlybecausethevalue-addedforfairvalueoftheassetsgeneratedfromacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdbyGuodaDrugstoreinthePeriod,arerecognizedtocorrespondingthedeferredincometaxliability;
11.Othernon-currentliabilities:anincreaseof318.5282millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof434.81%,mainlyduetotheadvancepaymentforpurchasingthegovernmentemergencyspecialreservematerialsinpreventionandcontrollingtheCOVID-19epidemic;
12.Financecosts:anincreaseof13.411millionYuanonayear-on-yearbasis,withagrowthrateof85.97%,mainlyduetothe
implementationofnewleasingstandards;
13.Impairmentlosses:anincreaseof1.0819millionYuanonayear-on-yearbasis,withagrowthrateof209.44%,mainlybecausetheprovisionforinventorydeclineinpricesinthecurrentperiodincreasedonay-o-ybasis;
14.Creditimpairmentlosses:anincreaseof12.4452millionYuanonayear-on-yearbasis,withagrowthrateof282.86%,mainlybecausetheendingaccountreceivableincreasedfromayearearlierfortheexpansionofsalesscale,andatthesametime,affectedbyCOVID-19epidemic,theturnoverdaysofreceivableshaveincreased,andtheprovisionforbaddebtshaveincreasedaccordingly.
15.Otherincomes:anincreaseof12.0434millionYuanonayear-on-yearbasis,withagrowthrateof1,105.17%,mainlybecausetheincreaseofTaxreliefandvariousspecialgrantsreceivedinthisperiod;
16.Investmentincome:adecreaseof22.707millionYuanonayear-on-yearbasis,withagrowthrateof-34.73%,mainlybecausetheinvestmentincomefromassociatesdeclinedfromayearearlier;
17.Gainondisposalofassets:adecreaseof247,055.53Yuanonayear-on-yearbasis,withagrowthrateof-1,738.69%,mainlyduetothelossfromsurrenderofretailpremisesforimplementingthenewleasingstandard,whilenosuchmatteroccurredlastyear;
18.Non-operatingexpenses:anincreaseof1.3356millionYuanonayear-on-yearbasis,withagrowthrateof356.39%,mainlyduetotheincreaseinfinesinthisperiod;
19.Othercashreceiptsrelatingtooperatingactivities:anincreaseof295.9483millionYuanonayear-on-yearbasis,withagrowthrateof215.29%,mainlyduetothereceiptofspecialreservefundsforthepreventionandcontroloftheCOVID-19,nosuchmatterinthesameperiodoflastyear;
20.Cashreceivedfromreturnsoninvestments:adecreaseof1.053millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecausereceivedcashdividendsfromassociatesinthesameperiodoflastyear,whilenosuchmatterintheperiod;
21.Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets:anincreaseof35,352.18Yuanonayear-on-yearbasis,withagrowthrateof49.05%,mainlyduetotheincreaseincashreceivedfromthedisposaloffixedassetsduringtheperiod;
22.Othercashreceiptsrelatingtoinvestingactivities:adecreaseof166.5millionYuanonayear-on-yearbasis,withagrowthrateof-88.33%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,andreceivedanaccountfromthecashpoolofformerparentcompany-SinopharmGroupCo.,Ltd,andrecoverthefundoriginallycollectedinthecashpoolintheperiod;
23.Sub-totalofcashinflowsfrominvestingactivities:adecreaseof167.5176millionYuanonayear-on-yearbasis,withagrowthrateof-88.34%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,andreceivedanaccountfromthecashpoolofformerparentcompany-SinopharmGroupCo.,Ltd,andrecoverthefundoriginallycollectedinthecashpoolintheperiod;
24.Cashpaymentsforinvestments:adecreaseof8.781millionYuanonayear-on-yearbasis,withagrowthrateof-43.64%,mainlybecausethetransferamountpaidforretailstoreacquisitionbysubsidiaryGuodaDrugstoredeclinedfromayearearlier;
25.Netcashpaidforacquisitionofsubsidiariesandotherbusinessunits:anincreaseof664.8827millionYuanonayear-on-yearbasis,withagrowthrateof100%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdfromsubsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
26.Othercashpaymentsrelatingtoinvestingactivities:adecreaseof116.5382millionYuanonayear-on-yearbasis,withagrowthrateof-73.80%,mainlybecauseintheperiod,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwasmergedbysubsidiaryGuodaDrugstoreunderthesamecontrol,thecashpoolwascollectedtoformerparentcompany-SinopharmGroupCo.,Ltd,whilenosuchmatterintheperiod;
27.Sub-totalofcashoutflowsfrominvestingactivities:anincreaseof535.6961millionYuanonayear-on-yearbasis,withagrowthrateof230.80%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,LtdfromsubsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
28.Netcashflowsfrominvestingactivities:adecreaseof703.2137millionYuanonayear-on-yearbasis,withagrowthrateof-1,655.61%,mainlyduetothenetcashpaidforacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltdfrom
subsidiaryGuodaDrugstore,andnosuchmatterinthesameperiodoflastyear;
29.Cashproceedsfrominvestmentsbyothers:adecreaseof4.392millionYuanonayear-on-yearbasis,withagrowthrateof-100%,mainlybecausereceivedcapitalincreasefromminorityshareholdersinthesameperiodlastyearwhilenosuchmatterintheperiod;
30.Cashreceivedfromborrowings:anincreaseof276.202millionYuanonayear-on-yearbasis,withagrowthrateof2,762.02%,mainlybecausereceivedspecialloanfundsforthepreventionandcontroloftheCOVID-19inthisperiod,andbankloansincreased;
31.Othercashreceiptsrelatingtofinancingactivities:anincreaseof138.1731millionYuanonayear-on-yearbasis,withagrowthrateof69.48%,mainlybecausethereturnofmoneyorderreceivedintheperiodhasincreasedfromayearearlier,andreceivedfundsborrowedfromnon-financialinstitutions,whilenosuchmatterinthesameperiodoflastyear;
32.Sub-totalofcashinflowsfromfinancingactivities:anincreaseof409.9831millionYuanonayear-on-yearbasis,withagrowthrateof192.23%,mainlybecausereceivedspecialloanfundsforthepreventionandcontroloftheCOVID-19inthisperiod,andthemoneyorderdepositreceivedintheperiodincreasedonay-o-ybasis;
33.Cashrepaymentsfordebts:anincreaseof75.5384millionYuanonayear-on-yearbasis,withagrowthrateof113.49%,mainlyduetotheincreaseinrepaymentofloansintheperiod;
34.Othercashpaymentsrelatingtofinancingactivities:anincreaseof441.6207millionYuanonayear-on-yearbasis,withagrowthrateof1,381.06%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
35.Sub-totalofcashoutflowsfromfinancingactivities:anincreaseof497.1017millionYuanonayear-on-yearbasis,withagrowthrateof271.24%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
36.Netcashflowsfromfinancingactivities:adecreaseof87.1187millionYuanonayear-on-yearbasis,withagrowthrateof-290.37%,mainlybecauseimplementthenewleasingstandard,andtheinvestmentpaidformergedofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore;
37.Effectofforeignexchangeratechangesoncashandcashequivalents:adecreaseof239.99Yuanonayear-on-yearbasis,withagrowthrateof-39.66%,mainlyduetotheimpactofexchangeratefluctuations;
38.Netincreaseofcashandcashequivalents:adecreaseof690.2282millionYuanonayear-on-yearbasis,withagrowthrateof-86.19%,mainlyduetothenetcashpaidbytheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.andtheinvestmentpaymentforthemergerofPudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolfromsubsidiaryGuodaDrugstore,nosuchmatterinthesameperiodoflastyear.II.Analysisandexplanationofsignificanteventsandtheirinfluenceandsolutions
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√NotapplicableIII.CommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies
□Applicable√NotapplicableTheCompanyhasnocommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies.
IV.Securitiesinvestment
□Applicable√Notapplicable
NosecurityinvestmentinthePeriod.
V.Trustfinancing
□Applicable√Notapplicable
NotrustfinancinginthePeriod.
VI.Derivativeinvestment
□Applicable√NotapplicableNoderivativeinvestmentinthePeriod.
VII.Registrationformforreceivingresearch,communicationandinterviewinthereportperiod
□Applicable√Notapplicable
TheCompanyhadnoreceivingresearch,communicationorinterviewinthereportperiod.
VIII.Guaranteeoutsideagainsttheregulation
□Applicable√Notapplicable
TheCompanyhadnoguaranteeoutsideagainsttheregulationintheperiod.
IX.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationformcontrollingshareholdersanditsrelatedpartyintheperiod.
SectionIV.FinancialStatementI.Financialstatement
1.Consolidatebalancesheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
InRMB
Items | 2020-3-31 | 2019-12-31 |
Currentassets: | ||
Cashandbankbalances | 7,343,918,788.98 | 8,885,729,250.47 |
Settlementprovisions | ||
Capitallent | ||
Tradingfinancialassets | ||
Derivativefinancialassets | ||
Notesreceivable | 523,366,192.20 | 788,024,326.05 |
Accountsreceivable | 12,800,950,512.29 | 10,712,983,544.18 |
Receivablesfinancing | 488,648,048.49 | 451,619,951.05 |
Advancestosuppliers | 777,145,678.93 | 389,828,785.54 |
Insurancereceivable | ||
Reinsurancereceivables | ||
Contractreserveofreinsurancereceivable | ||
Otherreceivables | 601,307,772.09 | 501,958,841.43 |
Including:Interestreceivable | - | - |
Dividendreceivable | - | 834,914.61 |
Buyingbackthesaleoffinancialassets | ||
Inventories | 5,906,648,659.90 | 5,063,274,143.26 |
Contractualassets | ||
Assetsheldforsale | ||
Non-currentassetduewithinoneyear | ||
Othercurrentassets | 102,839,050.54 | 102,207,498.20 |
Totalcurrentassets | 28,544,824,703.42 | 26,895,626,340.18 |
Non-currentassets: | ||
Loansandpaymentsonbehalf | ||
Debtinvestment | ||
Otherdebtinvestment | ||
Long-termaccountreceivable | ||
Long-termequityinvestment | 2,148,499,112.76 | 2,105,114,410.88 |
Otherequityinstrumentinvestment | 116,021,000.00 | 116,021,000.00 |
Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
Investmentproperties | 137,294,164.25 | 138,900,358.30 |
Fixedassets | 705,749,195.67 | 709,320,467.92 |
Constructioninprogress | 22,928,901.67 | 31,582,575.84 |
Productivebiologicalasset | ||
Oilandgasasset | ||
Right-of-useassets | 2,067,046,282.85 | 1,994,757,862.07 |
Intangibleassets | 635,390,640.10 | 375,145,507.81 |
ExpenseonResearchandDevelopment | ||
Goodwill | 1,513,175,733.86 | 1,010,057,927.17 |
Long-termprepaidexpenses | 359,836,930.28 | 373,527,968.14 |
Deferredtaxassets | 77,752,777.11 | 63,110,829.12 |
Othernon-currentasset | 414,121,238.65 | 77,354,970.39 |
Totalnon-currentasset | 8,337,815,977.20 | 7,134,893,877.64 |
Totalassets | 36,882,640,680.62 | 34,030,520,217.82 |
Currentliabilities: | ||
Short-termborrowings | 2,785,253,982.80 | 1,453,018,300.01 |
Loanfromcentralbank | ||
Capitalborrowed | ||
Tradingfinancialliability | ||
Derivativefinancialliability | ||
Notespayable | 4,680,238,916.43 | 5,555,697,557.53 |
Accountspayable | 7,674,022,927.20 | 6,703,967,826.54 |
Accountsreceivedinadvance | - | - |
Contractliabilities | 310,277,865.26 | 303,194,940.70 |
Sellingfinancialassetofrepurchase | ||
Absorbingdepositandinterbankdeposit | ||
Securitytradingofagency | ||
Securitysalesofagency | ||
Employeebenefitspayable | 191,026,038.97 | 259,640,813.10 |
Taxespayable | 215,540,339.83 | 253,379,524.34 |
Otherpayables | 2,696,831,680.78 | 1,822,364,637.62 |
Including:Interestpayable | 19,775,863.45 | 23,632,632.90 |
Dividendpayable | 44,377,935.76 | 6,389,320.96 |
Commissionchargeandcommissionpayable | ||
Reinsurancepayable | ||
Liabilityheldforsale | ||
Non-currentliabilitiesduewithinoneyear | 619,613,745.74 | 611,917,847.37 |
Othercurrentliabilities | 810,273.49 | 749,710.19 |
Totalcurrentliabilities | 19,173,615,770.50 | 16,963,931,157.40 |
Non-currentliabilities: | ||
Insurancecontractreserve | ||
Long-termborrowings | ||
Bondspayable | ||
Including:Preferredstock | ||
Perpetualcapitalsecurities | ||
Leaseliabilities | 1,261,824,990.27 | 1,208,453,029.51 |
Long-termpayables | 800,000.00 | 800,000.00 |
Long-termemployeebenefitspayable | 1,433,000.00 | 1,433,000.00 |
Accrualliability | ||
Deferredincome | 87,487,310.49 | 88,704,272.88 |
Deferredtaxliabilities | 180,619,768.58 | 118,704,213.68 |
Othernon-currentliabilities | 391,784,710.75 | 73,256,514.93 |
Totalnon-currentliabilities | 1,923,949,780.09 | 1,491,351,031.00 |
Totalliabilities | 21,097,565,550.59 | 18,455,282,188.40 |
Owner’sequity: | ||
Sharecapital | 428,126,983.00 | 428,126,983.00 |
Otherequityinstrument | ||
Including:Preferredstock | ||
Perpetualcapitalsecurities | ||
Capitalsurplus | 4,372,907,637.11 | 4,470,766,959.44 |
Less:Inventoryshares | ||
Othercomprehensiveincome | 45,909,846.02 | 45,917,342.77 |
Reasonablereserve | ||
Surplusreserves | 214,063,491.50 | 214,063,491.50 |
Provisionofgeneralrisk | ||
Retainedearnings | 8,001,632,303.78 | 7,752,831,647.90 |
Shareholders’equityattributabletoshareholdersoftheparent | 13,062,640,261.41 | 12,911,706,424.61 |
Non-controllinginterests | 2,722,434,868.62 | 2,663,531,604.81 |
Totalshareholders’equity | 15,785,075,130.03 | 15,575,238,029.42 |
Totalliabilitiesandshareholders’equity | 36,882,640,680.62 | 34,030,520,217.82 |
LegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitute:WangYing
2.BalanceSheetofParentCompany
InRMB
Item | 2020-3-31 | 2019-12-31 |
Currentassets: | ||
Cashandbankbalances | 2,822,146,959.33 | 2,909,417,289.71 |
Tradingfinancialassets | ||
Derivativefinancialassets | ||
Notesreceivable | 12,331,708.43 | 14,900,068.42 |
Accountsreceivable | 594,814,676.12 | 571,544,784.65 |
Receivablefinancing | 3,377,820.85 | 30,194,682.11 |
Advancestosuppliers | 13,142,791.24 | 7,996,243.28 |
Otherreceivables | 2,084,765,484.28 | 1,928,941,595.38 |
Including:Interestreceivable | ||
Dividendreceivable | 834,914.61 | 834,914.61 |
Inventories | 216,005,001.01 | 169,422,075.78 |
Contractualassets | ||
Assetsheldforsale | ||
Non-currentassetsmaturingwithinoneyear | ||
Othercurrentassets | 39,482.38 | 39,482.38 |
Totalcurrentassets | 5,746,623,923.64 | 5,632,456,221.71 |
Non-currentassets: | ||
Debtinvestment | ||
Otherdebtinvestment | ||
Long-termreceivables | ||
Long-termequityinvestments | 7,736,253,202.12 | 7,698,756,525.83 |
Investmentinotherequityinstrument | ||
Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
Investmentproperties | 1,476,181.93 | 1,484,198.56 |
Fixedassets | 13,843,610.76 | 14,763,656.62 |
Constructioninprogress | ||
Productivebiologicalassets | ||
Oilandnaturalgasassets | ||
Right-of-useassets | 5,937,816.70 | 6,217,504.50 |
Intangibleassets | 5,489,250.88 | 5,838,737.17 |
Researchanddevelopmentcosts | ||
Goodwill | ||
Long-termprepaidexpenses | 5,620,360.05 | 6,130,534.55 |
Deferredtaxassets | 9,301,194.10 | 9,327,850.53 |
Othernon-currentassets | 24,058,875.73 | 9,000,000.00 |
Totalnon-currentassets | 7,941,980,492.27 | 7,891,519,007.76 |
Totalassets | 13,688,604,415.91 | 13,523,975,229.47 |
Currentliabilities | ||
Short-termborrowings | 165,998,444.54 | 121,350,644.36 |
Tradingfinancialliability |
Derivativefinancialliability | ||
Notespayable | 451,394,209.68 | 751,577,900.22 |
Accountspayable | 353,628,404.84 | 322,436,681.01 |
Accountsreceivedinadvance | ||
Contractliabilities | 11,429,537.40 | 7,293,184.46 |
Employeebenefitspayable | 19,083,766.42 | 30,469,777.88 |
Taxepayable | 11,257,362.50 | 22,909,124.90 |
Otherpayables | 2,366,308,945.51 | 2,120,794,765.05 |
Including:Interestpayable | 509,597.78 | 861,110.53 |
Dividendpayable | ||
Liabilityheldforsale | ||
Non-currentliabilitiesduewithinoneyear | 32,651,734.15 | 32,640,325.77 |
Othercurrentliabilities | 314,047.05 | 338,196.81 |
Totalcurrentliabilities | 3,412,066,452.09 | 3,409,810,600.46 |
Non-currentliabilities: | ||
Long-termloans | ||
Bondspayable | ||
Including:preferredstock | ||
Perpetualcapitalsecurities | ||
Leaseliabilities | 5,203,186.76 | 5,461,257.38 |
Long-termpayables | 800,000.00 | 800,000.00 |
Longtermemployeecompensationpayable | ||
Accruedliabilities | ||
Deferredincome | 1,164,438.54 | 1,276,698.66 |
Deferredincometaxliabilities | ||
Othernon-currentliabilities | 90,748,869.74 | |
Totalnon-currentliabilities | 97,916,495.04 | 7,537,956.04 |
Totalliabilities | 3,509,982,947.13 | 3,417,348,556.50 |
Owners’equity: | ||
Sharecapital | 428,126,983.00 | 428,126,983.00 |
Otherequityinstrument | ||
Including:preferredstock |
Perpetualcapitalsecurities | ||
Capitalpublicreserve | 4,468,385,307.32 | 4,468,385,307.32 |
Less:Inventoryshares | ||
Othercomprehensiveincome | -133,366.19 | -133,366.19 |
Specialreserve | ||
Surplusreserves | 214,063,491.50 | 214,063,491.50 |
Retainedearnings | 5,068,179,053.15 | 4,996,184,257.34 |
Totalshareholders’equity | 10,178,621,468.78 | 10,106,626,672.97 |
Totalliabilitiesandshareholders’equity | 13,688,604,415.91 | 13,523,975,229.47 |
3.ConsolidatedProfitStatement
InRMB
Item | Currentperiod | Lastperiod |
I.Totaloperatingrevenue | 12,824,196,278.66 | 12,071,656,553.13 |
Including:operatingrevenue | 12,824,196,278.66 | 12,071,656,553.13 |
Interestincome | ||
Insurancegained | ||
Commissionchargeandcommissionincome | ||
II.Totaloperatingcosts | 12,488,521,944.35 | 11,708,131,977.39 |
Including:Operatingcost | 11,370,970,742.96 | 10,734,553,498.15 |
Interestexpense | ||
Commissionchargeandcommissionexpense | ||
Cashsurrendervalue | ||
Netamountofexpenseofcompensation | ||
Netamountofwithdrawalofinsurancecontractreserve | ||
Bonusexpenseofguaranteeslip | ||
Reinsuranceexpense | ||
Taxandsurcharges | 29,109,421.79 | 30,631,231.08 |
Sellingexpenses | 844,624,826.78 | 742,825,433.15 |
Administrativeexpense | 214,805,866.61 | 184,521,686.12 |
R&Dexpense |
Financecosts | 29,011,086.21 | 15,600,128.89 |
Including:Interestcost | 60,067,901.98 | 44,592,359.04 |
Interestincome | 29,094,889.11 | 29,675,288.29 |
Add:otherincomes | 13,133,111.50 | 1,089,732.58 |
Investmentincome(Lossislistedwith“-”) | 42,676,071.54 | 65,383,095.99 |
Including:Investmentincomefromassociates | 60,020,272.13 | 81,891,387.17 |
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | -18,342,866.43 | -16,508,291.18 |
Exchangeincome(Lossislistedwith“-”) | ||
Netexposurehedgingincome(Lossislistedwith“-”) | ||
Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
Creditimpairmentlosses(Lossislistedwith“-”) | -16,845,052.13 | -4,399,838.33 |
Impairmentlosses(Lossislistedwith“-”) | -1,598,436.71 | -516,563.77 |
Gainondisposalofassets(Lossislistedwith“-”) | -261,264.83 | -14,209.30 |
III.Operatingprofit(Lossislistedwith“-”) | 372,778,763.68 | 425,066,792.91 |
Add:Non-operatingincome | 1,811,729.05 | 1,840,452.50 |
Less:Non-operatingexpenses | 1,710,329.13 | 374,748.81 |
IV.Totalprofit(Lossislistedwith“-”) | 372,880,163.60 | 426,532,496.60 |
Less:Incometaxes | 77,791,885.48 | 81,751,622.22 |
V.Netprofit(Netlossislistedwith“-”) | 295,088,278.12 | 344,780,874.38 |
(i)Classifybybusinesscontinuity | ||
1.Netprofitfromcontinuousoperation(netlosslistedwith‘-”) | 295,088,278.12 | 344,780,874.38 |
2.Netprofitfromdiscontinuedoperation(netlosslistedwith‘-”) | ||
(ii)Classifybyownership | ||
1.Ownersoftheparent | 248,800,655.88 | 299,451,036.34 |
2.Non-controllinginterests | 46,287,622.24 | 45,329,838.04 |
VI.Netafter-taxofothercomprehensiveincome | ||
Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany | ||
(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
1.Changesofthedefinedbenefitplansthatre-measured | ||
2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
4.Fairvaluechangeofenterprise'screditrisk | ||
5.Other | ||
(ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
2.Changeoffairvalueofotherdebtinvestment | ||
3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
4.Creditimpairmentprovisionforotherdebtinvestment | ||
5.Cashflowhedgingreserve | ||
6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
7.Other |
Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
VII.Totalcomprehensiveincome | 295,088,278.12 | 344,780,874.38 |
Totalcomprehensiveincomeattributabletoshareholdersoftheparent | 248,800,655.88 | 299,451,036.34 |
Totalcomprehensiveincomeattributabletonon-controllinginterests | 46,287,622.24 | 45,329,838.04 |
VIII.Earningspershare: | ||
(i)Basicearningspershare | 0.58 | 0.70 |
(ii)Dilutedearningspershare | 0.58 | 0.70 |
EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof-2,057,252.42Yuanbeforecombination,andrealized1,711,604.94YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitute:WangYing
4.ProfitStatementofParentCompany
InRMB
Item | Currentperiod | Lastperiod |
I.Operatingrevenue | 883,090,683.07 | 980,473,288.29 |
Less:Operatingcosts | 850,760,365.77 | 941,804,760.61 |
Taxandsurcharges | 1,011,193.50 | 1,316,238.98 |
Sellingexpenses | 16,302,891.84 | 14,925,549.11 |
Administrativeexpenses | 22,374,408.72 | 14,279,164.82 |
R&Dexpenses | ||
Financecosts | -22,842,676.94 | -14,512,152.70 |
Including:Interestcost | 9,151,290.82 | 9,720,694.28 |
Interestincome | 32,061,791.21 | 24,381,516.96 |
Add:otherincomes | 293,056.51 | 193,207.80 |
Investmentincome(Lossislistedwith“-”) | 60,592,685.27 | 87,255,527.95 |
Including:Investmentincomefromassociates | 60,134,457.45 | 87,865,487.39 |
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost | -540,438.02 | -609,959.44 |
Netexposurehedgingincome(Lossislistedwith“-”) | ||
Changingincomeoffairvalue(Lossislistedwith“-”) | ||
Creditimpairmentlosses(Lossislistedwith“-”) | -973,888.89 | |
Impairmentlosses(Lossislistedwith“-”) | 217,422.14 | -361,970.94 |
Incomeondisposalofassets(Lossislistedwith“-”) | ||
II.Operatingprofit(Lossislistedwith“-”) | 75,613,775.21 | 109,746,492.28 |
Add:Non-operatingincome | 1,578.11 | 45,736.26 |
Less:Non-operatingexpenses | ||
III.TotalProfit(Lossislistedwith“-”) | 75,615,353.32 | 109,792,228.54 |
Less:Incometaxes | 3,620,557.51 | 5,482,579.40 |
IV.Netprofit(Netlossislistedwith“-”) | 71,994,795.81 | 104,309,649.14 |
(i)Netprofitfromcontinuousoperation(netlosslistedwith‘-”) | 71,994,795.81 | 104,309,649.14 |
(ii)Netprofitfromdiscontinuedoperation(netlosslistedwith‘-”) | ||
V.Netafter-taxofothercomprehensiveincome | ||
(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
1.Changesofthedefinedbenefitplansthatre-measured | ||
2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
3.Changeoffairvalueofinvestmentinotherequityinstrument |
4.Fairvaluechangeofenterprise'screditrisk | ||
5.Other | ||
(II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
2.Changeoffairvalueofotherdebtinvestment | ||
3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
4.Creditimpairmentprovisionforotherdebtinvestment | ||
5.Cashflowhedgingreserve | ||
6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
7.Other | ||
VI.Totalcomprehensiveincome | 71,994,795.81 | 104,309,649.14 |
VII.Earningspershare: | ||
(i)Basicearningspershare | ||
(ii)Dilutedearningspershare |
5.ConsolidatedCashFlowStatement
InRMB
Item | Currentperiod | Lastperiod |
I.Cashflowsfromoperatingactivities: | ||
Cashreceivedfromsaleofgoodsorrenderingofservices | 13,201,992,638.81 | 11,447,434,730.14 |
Netincreaseofcustomerdepositandinterbankdeposit | ||
Netincreaseofloanfromcentralbank |
Netincreaseofcapitalborrowedfromotherfinancialinstitution | ||
Cashreceivedfromoriginalinsurancecontractfee | ||
Netcashreceivedfromreinsurancebusiness | ||
Netincreaseofinsuredsavingsandinvestment | ||
Cashreceivedfrominterest,commissionchargeandcommission | ||
Netincreaseofcapitalborrowed | ||
Netincreaseofreturnedbusinesscapital | ||
Netcashreceivedbyagentsinsaleandpurchaseofsecurities | ||
Receiptsoftaxesandsurchargesrefunds | 775,261.38 | - |
Othercashreceiptsrelatingtooperatingactivities | 433,415,062.71 | 137,466,777.68 |
Sub-totalofcashinflowsfromoperatingactivities | 13,636,182,962.90 | 11,584,901,507.82 |
Cashpaidforgoodsandservices | 12,827,089,312.11 | 11,082,205,912.68 |
Netincreaseofcustomerloansandadvances | ||
Netincreaseofdepositsincentralbankandinterbank | ||
Cashpaidfororiginalinsurancecontractcompensation | ||
Netincreaseofcapitallent | ||
Cashpaidforinterest,commissionchargeandcommission | ||
Cashpaidforbonusofguaranteeslip | ||
Cashpaidtoandonbehalfofemployees | 703,922,606.95 | 594,165,778.91 |
Cashpaidforalltypesoftaxes | 368,976,475.15 | 328,266,367.46 |
Othercashpaymentsrelatingtooperatingactivities | 424,468,417.32 | 368,641,736.27 |
Sub-totalofcashoutflowsfromoperatingactivities | 14,324,456,811.53 | 12,373,279,795.32 |
Netcashflowsfromoperatingactivities | -688,273,848.63 | -788,378,287.50 |
II.Cashflowsfrominvestingactivities: | ||
Cashreceivedfromrecoveringinvestment | ||
Cashreceivedfromreturnsoninvestments | 1,053,000.00 | |
Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 107,430.91 | 72,078.73 |
Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
Othercashreceiptsrelatingtoinvestingactivities | 22,000,000.00 | 188,500,000.00 |
Sub-totalofcashinflowsfrominvestingactivities | 22,107,430.91 | 189,625,078.73 |
Cashpaidforacquisitionoffixedassetsintangibleassetsandotherlong-termassets | 50,207,587.50 | 54,074,916.12 |
Cashpaymentsforinvestments | 11,341,032.15 | 20,122,074.00 |
Netincreaseofmortgagedloans | ||
Netcashpaidforacquisitionofsubsidiariesandotherbusinessunits | 664,882,681.20 | |
Othercashpaymentsrelatingtoinvestingactivities | 41,364,521.11 | 157,902,761.38 |
Sub-totalofcashoutflowsfrominvestingactivities | 767,795,821.96 | 232,099,751.50 |
Netcashflowsfrominvestingactivities | -745,688,391.05 | -42,474,672.77 |
III.Cashflowsfromfinancingactivities | ||
Cashproceedsfrominvestmentsbyothers | 4,392,000.00 | |
Including:Cashproceedsfromsubsidiaryinvestmentsbynon-controllingshareholders | 4,392,000.00 | |
Cashreceivedfromborrowings | 286,202,002.73 | 10,000,000.00 |
Othercashreceiptsrelatingtofinancingactivities | 337,054,182.02 | 198,881,105.78 |
Sub-totalofcashinflowsfromfinancingactivities | 623,256,184.75 | 213,273,105.78 |
Cashrepaymentsfordebts | 142,100,000.00 | 66,561,634.53 |
Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 64,675,017.27 | 84,732,347.73 |
Including:Profitanddividendspaidtonon-controllingshareholdersofsubsidiaries | 1,558,470.71 | |
Othercashpaymentsrelatingtofinancingactivities | 473,597,592.59 | 31,976,889.98 |
Sub-totalofcashoutflowsfromfinancingactivities | 680,372,609.86 | 183,270,872.24 |
Netcashflowsfromfinancingactivities | -57,116,425.11 | 30,002,233.54 |
IV.effectofforeignexchangeratechangesoncashandcashequivalents | 365.20 | 605.19 |
V.Netincreaseofcashandcashequivalents | -1,491,078,299.59 | -800,850,121.54 |
Add:Cashandcashequivalentsatbeginningoftheyear | 8,426,071,170.16 | 7,644,975,994.75 |
VI.Cashandcashequivalentsatendofyear | 6,934,992,870.57 | 6,844,125,873.21 |
6.CashFlowStatementofParentCompany
InRMB
Item | Currentperiod | Lastperiod |
I.Cashflowsfromoperatingactivities: | ||
Cashreceivedfromsaleofgoodsorrenderingofservices | 1,062,518,589.11 | 979,117,418.50 |
Receiptsoftaxesandsurchargesrefunds | ||
Othercashreceiptsrelatingtooperatingactivities | 22,736,474.18 | 8,959,448.01 |
Sub-totalofcashinflowsfromoperatingactivities | 1,085,255,063.29 | 988,076,866.51 |
Cashpaidforgoodsandservices | 1,207,589,273.35 | 893,485,571.99 |
Cashpaidtoandonbehalfofemployees | 39,968,369.74 | 31,401,584.94 |
Cashpaidforalltypesoftaxes | 20,509,993.91 | 16,046,448.54 |
Othercashpaymentsrelatingtooperatingactivities | 14,820,413.79 | 9,310,459.60 |
Sub-totalofcashoutflowsfromoperatingactivities | 1,282,888,050.79 | 950,244,065.07 |
Netcashflowsfromoperatingactivities | -197,632,987.50 | 37,832,801.44 |
II.Cashflowsfrominvestingactivities: | ||
Cashreceivedfromrecoveringinvestment | 13,636,447.00 | |
Cashreceivedfromreturnsoninvestments | 16,895,775.01 | |
Netcashreceivedfromdisposaloffixed,intangibleandotherlong-termassets | ||
Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
Othercashreceiptsrelatingtoinvestingactivities | 602,709,245.48 | 442,400,000.00 |
Sub-totalofcashinflowsfrominvestingactivities | 616,345,692.48 | 459,295,775.01 |
Cashpaidforacquisitionoffixedassetsintangibleassetsandotherlong-termassets | 670,760.44 | 1,462,422.93 |
Cashpaidforinvestment | ||
Netcashreceivedfromsubsidiariesandotherunitsobtained | ||
Othercashpaymentsrelatingtoinvestingactivities | 792,214,521.11 | 629,400,000.00 |
Sub-totalofcashoutflowsfrominvestingactivities | 792,885,281.55 | 630,862,422.93 |
Netcashflowsfrominvestingactivities | -176,539,589.07 | -171,566,647.92 |
III.Cashflowsfromfinancingactivities | ||
Cashreceivedfromabsorbinginvestment | ||
Cashreceivedfromborrowings | 24,694,789.52 | 10,000,000.00 |
Othercashreceiptsrelatingtofinancingactivities | 8,004,663,212.88 | 4,517,196,050.81 |
Sub-totalofcashinflowsfromfinancingactivities | 8,029,358,002.40 | 4,527,196,050.81 |
Cashrepaymentsfordebts | 12,100,000.00 | 10,000,000.00 |
Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 9,363,675.10 | 6,245,437.77 |
Othercashpaymentsrelatingtofinancingactivities | 7,724,025,779.65 | 4,584,325,273.13 |
Sub-totalofcashoutflowsfromfinancingactivities | 7,745,489,454.75 | 4,600,570,710.90 |
Netcashflowsfromfinancingactivities | 283,868,547.65 | -73,374,660.09 |
IV.effectofforeignexchangeratechangesoncashandcashequivalents | 365.20 | 605.19 |
V.Netincreaseofcashandcashequivalents | -90,303,663.72 | -207,107,901.38 |
Add:Cashandcashequivalentsatbeginningoftheyear | 2,894,333,956.38 | 1,817,654,598.01 |
VI.Cashandcashequivalentsatendofyear | 2,804,030,292.66 | 1,610,546,696.63 |
II.Explanationonfinancialstatementadjustment
1.Financialstatementadjustmentatthebeginningofthefirstyearwhenimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√Notapplicable
2.Retrospectiveadjustmentofthecomparativedataforinitialimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√NotapplicableIII.AuditreportWhetherthe1
stquarterlyreporthasbeenauditedornot
□Yes√No1QreportoftheCompanyisunaudited.
ChinaNationalAccordMedicinesCorporationLtd.
Legalrepresentative:LinZhaoxiong
25April2020